Methylphenidate and brain dopamine neurotoxicity

Brain Research

Volumn 767, Issue 1, 1997, Pages 172-175

  Yuan, Jie ^a   McCann, Una ^b   Ricaurte, George ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

ADHD; Amphetamine; Dopamine; Narcolepsy; Neurotoxicity

Indexed keywords

AMPHETAMINE; DOPAMINE; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DOPAMINE RELEASE; DOSE RESPONSE; DRUG ABUSE; MALE; MOUSE; NARCOLEPSY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; STEREOTYPY; SUBCUTANEOUS DRUG ADMINISTRATION;

3,4-DIHYDROXYPHENYLACETIC ACID; ANALYSIS OF VARIANCE; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; DOPAMINE AGENTS; MALE; METHYLPHENIDATE; MICE;

EID: 0030773501     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00771-3     Document Type: Article

References (30)

1. Abekawa T., Ohmori T., Koyama T. Effects of repeated administration of a high dose of methamphetamine on dopamine and glutamate release in rat striatum and nucleus accumbens. Brain Res. 643:1994;276-281.
2. Chiueh C.C., Moore K.E. Blockade by reserpine of methylphenidate-induced release of brain dopamine. J. Pharmacol. Exp. Ther. 193:1975;559-563.
3. Ellison G., Eison M.S., Huberman H.S., Daniel F. Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration. Science. 201:1978;276-278.
4. 14C: studies in man and animals. J. Pharmacol. Exp. Ther. 19:1974;535-547.
5. G. Feussner, DEA, Drug and Chemical Evaluation Unit, Washington, DC, 1996.
6. Fuller R.W., Hemrick-Luecke S. Long-lasting depletion of striatal dopamine by a single injection of amphetamine in iprindole-treated rats. Science. 209:1980;395-397.
7. Holmes V.F. Medical use of psychostimulants: an overview. Int. J. Psychiatry Med. 25:1995;1-19.
8. Hurd Y.L., Ungerstedt U. In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen. Eur. J. Pharmacol. 166:1989;251-260.
9. L. Johnson, J. Bachman, P. O'Malley, Monitoring the Future, Survey Research Center Institute of Social Research, University of Michigan, Ann Arbor, MI, 1993.
10. Klein R.G. The role of methylphenidate in psychiatry. Arch. Gen. Psychiatry. 52:1995;429-433.
11. Kogan F.J., Nichols W.K., Gibb J.W. Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur. J. Pharmacol. 36:1976;363-371.
12. R. Kuczenski, Biochemical actions of amphetamine and other stimulants, in: I. Creese (Ed.), Stimulants: Neurochemical, Behavioral and Clinical Perspectives, Raven Press, New York, 1983, pp. 39-61.
13. Kuczenski R., Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J. Neurochem. 68(5):1997;2032-2037.
14. Mitler M.M. Evaluation of treatment with stimulants in narcolepsy. Sleep. 17:1994;S103-S106.
15. K.E. Moore, C.C. Chiueh, G. Zeldes, Release of neurotransmitters from brain in vivo by amphetamine, methylphenidate and cocaine, in: E. Ellinwood, M. Kilbey (Eds.), Cocaine and Other Stimulants, Plenum Press, New York, 1977, pp. 143-160.
16. O'Dell S.J., Weihmuller F.B., Marshall J.F. Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity. Brain Res. 564:1991;256-260.
17. Ricaurte G.A., Fuller R.W., Perry K.W., Seiden L.S., Schuster C.R. Fluoxetine increase long-lasting neostriatal dopamine depletion after administration of d-methamphetamine and d-amphetamine. Neuropharmacology. 22:1983;1165-1169.
18. Ricaurte G.A., Guillery R.W., Seiden L.S., Schuster C.R. Nerve terminal degeneration after a single injection of d-amphetamine in iprindole-treated rats: relation to selective long-lasting dopamine depletion. Brain Res. 291:1984;378-382.
19. Ricaurte G.A., Irwin I., Forno L.S., DeLanney L.E., Langston E., Langston J.W. Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res. 403:1987;43-51.
20. Ricaurte G.A., Seiden L.S., Schuster C.R. Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res. 303:1984;359-364.
21. Scanzello C.R., Hatzidimitriou G., Martello A.L., Katz J.L., Ricaurte G.A. Serotonergic recovery after (±)3,4-(methylenedioxy) methamphetamine injury: observations in rats. J. Pharmacol. Exp. Ther. 264:1993;1484-1491.
22. Schmidt C.J., Ritter J.K., Sonsalla P.K., Hanson G.R., Gibb J.W. Role of dopamine in the neurotoxic effects of methamphetamine. J. Pharmacol. Exp. Ther. 233:1985;539-544.
23. Seiden L.S., Fischman M.M., Schuster C.R. Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend. 1:1976;215-219.
24. L.S. Seiden, G.A. Ricaurte, Neurotoxicity of methamphetamine and related drugs, in: H.Y. Meltzer (Ed.), Psychopharmacology - A Generation of Progress, Raven Press, New York, 1987, pp. 359-366.
25. Sonsalla P.K., Heikkila R.E. Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methamphetamine in several strains of mice. Prog. Neuropsychopharmacol. Biol. Psychiatry. 12:1988;345-354.
26. Spencer T., Wilens T., Biederman J., Farone S.V., Ablon J.S., Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch. Gen. Psychiatry. 52:1995;434-443.
27. Wagner G.C., Lucot J.B., Schuster C.R., Seiden L.S. Alpha-methyltyrosine attenuates and reserpine increases methamphetamine-induced neuronal changes. Brain Res. 270:1983;285-288.
28. Wagner G.C., Ricaurte G.A., Johanson C.E., Schuster C.R., Seiden L.S. Amphetamine induces depletion of dopamine and loss of dopamine uptake sites in the caudate nucleus. Neurology. 30:1980;547-550.
29. Zaczek R., Battaglia G., Contrera J.F., Culp S., De Souza E.B. Methylphenidate and pemoline do not cause depletion of rat brain monoamine markers similar to that observed with methamphetamine. Toxicol. Appl. Pharmacol. 100:1989;227-233.
30. Zarcone V. Narcolepsy. New Engl. J. Med. 288:1973;1156-1166.